Skip to main content

Table 1 Baseline characteristics

From: Prognostic influence of body mass index and body weight gain during adjuvant FOLFOX chemotherapy in Korean colorectal cancer patients

   Body Mass Index  
  Total Normal or underweight Overweight Obese p-value*
≤ 22.9 kg/m2 23–24.9 kg/m2 ≥ 25 kg/m2
  N (%) N (%) N (%) N (%)  
Total 522 (100) 184 (35.2) 152 (29.1) 186 (35.6)  
Age      0.028
  < 65 years 366 (70.1) 138 (75.0) 108 (71.1) 120 (64.5) 0.42
  ≥ 65 years 156 (29.9) 46 (25.0) 44 (28.9) 66 (35.5) 0.028
Sex      0.094
 Male 312 (59.8) 99 (53.8) 97 (63.8) 116 (62.4) 0.064
 Female 210 (40.2) 85 (46.2) 55 (36.2) 70 (37.6) 0.095
Location      0.56
 Proximal 181 (34.7) 63 (34.2) 49 (32.2) 69 (37.1) 0.70
 Distal 341 (65.3) 121 (65.8) 103 (67.8) 117 (62.9) 0.57
T stage      0.17
 T1 - 3 446 (85.4) 149 (81.0) 137 (90.1) 160 (86.0) 0.019
 T4 76 (14.6) 35 (19.0) 15 (9.9) 26 (14.0) 0.19
N stage      0.96
 N0 - 1 380 (72.8) 133 (72.3) 113 (74.3) 134 (72.0) 0.67
 N2 142 (27.2) 51 (27.7) 39 (25.7) 52 (28.0) 0.96
Tumor stage     0.073
 II, high-risk 78 (14.9) 37 (20.1) 16 (10.5) 25 (13.4) 0.016
 III 444 (85.1) 147 (79.9) 136 (89.5) 161 (86.6) 0.086
Histology      0.15
 MAC 27 (5.2) 12 (6.5) 9 (5.9) 6 (3.2) 0.82
 Non-MAC 495 (94.8) 172 (93.5) 143 (94.1) 180 (96.8) 0.14
Microsatellite status (N = 517) 0.062
 MSS/MSI-L 480 (92.8) 163 (90.1) 142 (93.4) 175 (95.1) 0.27
 MSI-H 37 (7.2) 18 (9.9) 10 (6.6) 9 (4.9) 0.065
  1. Abbreviations: MAC mucinous adenocarcinoma, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high
  2. *Upper row: linear-by-linear association test, middle row: Χ2 test of normal or underweight vs. overweight, lower row: Χ2 test of normal or underweight vs. obese